Viking Therapeutics
VKTX on Nasdaq. Viking Therapeutics develops drugs for obesity and metabolic diseases and sells none yet. Market value $3.4bn.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Cash flow or capital spending isn't reported, so free cash flow is unknown.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$28.38 a share, 10% above its 1-year low
Over the past year the price has ranged from $25.77 to $43.15.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.08bn | 0.10bn | 0.11bn | 0.11bn | 0.12bn |
Health checks
- Free cash flow positiveNot enough data
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)1 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 52% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $128 million, compared with a loss of $66 million a year ago.
- 4% more shares than a year ago. Each share owns a bit less of the company.
- Sales did not grow on a year ago in any of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | -$25m |
| December 2024 | -$35m |
| March 2025 | -$46m |
| June 2025 | -$66m |
| September 2025 | -$91m |
| December 2025 | -$158m |
| March 2026 | -$158m |
| June 2026 | -$128m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 11 February 2026
- Next quarterly (estimated, 10-Q)
- 28 October 2026
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 434 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Gotham Asset ManagementJoel Greenblatt | $9m | <0.1% | Cut |
Largest holders overall
- FMR$247mAdded
- BlackRock$241mCut
- State Street$219mAdded
- Vanguard Capital Management$197m
- Vanguard Portfolio Management$175m
- TWO Sigma Investments, LP$154mCut
- Morgan Stanley$136mAdded
- Ameriprise Financial$84mAdded
- Geode Capital Management$82m
- American Century Companies$71mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- FMR LLCPassive investorat least 5.1%−3.6 pts(filed with 1 related holder)Since 30 September 2025
- Vanguard Capital ManagementPassive investor5.1%Since 31 March 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 31 March 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
FMR LLC Passive investor | at least 5.1%−3.6 pts (filed with 1 related holder) | 30 September 2025 | |
Vanguard Capital Management Passive investor | 5.1% | 31 March 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 31 March 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $149,913 of shares on the open market. 5 sold $22m.
- Lian BrianPresident & CEO, DirectorSold
- Date
- 29 July 2026
- Shares
- 148,517
- Price
- $33.32
- Value
- $5m
- ZANTE GREGChief Financial OfficerSold
- Date
- 29 July 2026
- Shares
- 21,217
- Price
- $33.47
- Value
- $710,141
- Mancini MariannaChief Operating OfficerSold
- Date
- 29 July 2026
- Shares
- 18,217
- Price
- $33.47
- Value
- $609,636
- Aubuchon Neil WilliamChief Commercial OfficerBought
- Date
- 10 March 2026
- Shares
- 4,475
- Price
- $33.50
- Value
- $149,913
- ZANTE GREGChief Financial OfficerSold
- Date
- 5 January 2026
- Shares
- 57,661
- Price
- $32.90
- Value
- $2m
- Mancini MariannaChief Operating OfficerSold
- Date
- 5 January 2026
- Shares
- 57,661
- Price
- $32.97
- Value
- $2m
- Lian BrianPresident & CEO, DirectorSold
- Date
- 5 January 2026
- Shares
- 233,409
- Price
- $32.96
- Value
- $8m
- FOEHR MATTHEW WDirectorSold
- Date
- 2 January 2026
- Shares
- 16,000
- Price
- $35.11
- Value
- $561,760
- Mancini MariannaChief Operating OfficerSold
- Date
- 28 October 2025
- Shares
- 6,185
- Price
- $35.00
- Value
- $216,475
- Lian BrianPresident & CEO, DirectorSold
- Date
- 28 October 2025
- Shares
- 38,989
- Price
- $35.01
- Value
- $1m
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 29 July 2026 | Lian Brian President & CEO, Director | Sold | 148,517 | $33.32 | $5m |
| 29 July 2026 | ZANTE GREG Chief Financial Officer | Sold | 21,217 | $33.47 | $710,141 |
| 29 July 2026 | Mancini Marianna Chief Operating Officer | Sold | 18,217 | $33.47 | $609,636 |
| 10 March 2026 | Aubuchon Neil William Chief Commercial Officer | Bought | 4,475 | $33.50 | $149,913 |
| 5 January 2026 | ZANTE GREG Chief Financial Officer | Sold | 57,661 | $32.90 | $2m |
| 5 January 2026 | Mancini Marianna Chief Operating Officer | Sold | 57,661 | $32.97 | $2m |
| 5 January 2026 | Lian Brian President & CEO, Director | Sold | 233,409 | $32.96 | $8m |
| 2 January 2026 | FOEHR MATTHEW W Director | Sold | 16,000 | $35.11 | $561,760 |
| 28 October 2025 | Mancini Marianna Chief Operating Officer | Sold | 6,185 | $35.00 | $216,475 |
| 28 October 2025 | Lian Brian President & CEO, Director | Sold | 38,989 | $35.01 | $1m |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.